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Abstract
Regional citrate anticoagulation (RCA) is now recommended over systemic heparin for continuous renal replacement
therapy in patients without contraindications. Its use is likely to increase throughout the world. However, in the
absence of citrate blood level monitoring, the diagnosis of citrate accumulation, the most feared complication of RCA,
remains relatively complex. It is therefore commonly mistaken with other conditions. This review aims at providing
clarifications on RCA-associated acid-base disturbances and their management at the bedside. In particular, the authors
wish to propose a clear distinction between citrate accumulation and net citrate overload.
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Introduction
Anticoagulation is required during continuous renal
replacement therapy (CRRT) to maintain circuit patency.
Heparin has historically been the standard choice for
anticoagulation [1]. Unfortunately, in fear of bleeding
complications, heparin is often administered at sub-
therapeutic doses and frequently interrupted for procedures.
The resulting anticoagulation is commonly insufficient, lead-
ing to poor filter life [2].
Regional citrate anticoagulation (RCA) is an appealing
alternative since it provides excellent anticoagulation
within the circuit without increasing the risk of bleeding
[2, 3]. In randomized controlled trials [4–6] and meta-
analyses [7, 8], RCA has been shown to increase filter life
and decrease the rate of complications, therapy interrup-
tions, and costs compared with heparin. RCA has been
used in large tertiary centers with very low complication
rates [9]. RCA is now recommended as the first line antic-
oagulation strategy for CRRT in patients without contrain-
dications [10].
Given these recommendations, RCA is likely to be
gradually adopted in an increasing number of centers,
including smaller and non-academic hospitals with less
experience with CRRT. The implementation of RCA
requires particularly strict protocols and specific training
of both medical and nursing staff. Indeed, unguided
RCA might lead to potentially disastrous complications off-
setting its potential benefits. Currently published literature
might lead to some confusion regarding the interpretation
of RCA complications, in particular regarding acid-base
derangements.
This viewpoint aims at providing clarifications on
citrate-associated acid-base disturbances and their man-
agement at the bedside. In particular, the authors wish
to propose a clear distinction between citrate accumula-
tion and citrate overload, two intertwined notions, which
are commonly confused.
General principles
Principles of citrate anticoagulation
Citrate (C6H5O7) is an organic acid. It is commonly used
as an anticoagulant as trisodium citrate and, for stored
blood products, as acid citrate dextrose (ACD). Citrate
anticoagulant properties are related to its high affinity
for the divalent calcium ion (Ca++). The addition of cit-
rate to blood results in the formation of citrate–calcium
complexes (CCC), effectively decreasing the level of ion-
ized free calcium. Ionized magnesium is also chelated by
citrate but to a lesser extent. Since calcium is a
mandatory co-factor of most enzymes of the coagulation
cascade, citrate-mediated decrease in plasma calcium
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levels below 0.35 mmol/l results in very effective antic-
oagulation (Fig. 1) [11, 12].
Numerous protocols for RCA have been proposed and
tested [13, 14]. They differ by solution type (ACD, triso-
dium citrate, diluted citrate solutions) and CRRT modal-
ity (continuous veno-venous hemofiltration (CVVH),
continuous veno-venous hemodialysis (CVVHD), con-
tinuous veno-venous hemodiafiltration (CVVHDF)). All
these protocols require pre-filter administration of a cit-
rate solution at the required dose to reach approximately
3 to 4 mmol of citrate per liter of blood in the circuit.
Such a dose is usually sufficient to decrease ionized cal-
cium to the target range (0.2 to 0.35 mmol/l according
to the protocol used). Post-filter calcium is monitored to
ensure adequate anticoagulation and permit citrate dose
adjustment according to pre-defined models. In current
CRRT machines, citrate administration rate is coupled
with blood flow, minimizing the risk of variation in cit-
rate concentration. A calcium chloride solution needs to
be administered either at the end of the circuit or dir-
ectly through a separated central line to compensate for
calcium loss in the effluent in the form of CCC (Fig. 2).
Calcium reinfusion rate is adjusted according to sequen-
tially measured systemic ionized calcium level (targeting
physiological range). After the initiation phase, regular
monitoring (every 6 h) of post-filter, systemic, and total
calcium levels (with total/ionized ratio calculation)
should be performed. Since, according to the compos-
ition of dialysate/replacement fluids used, magnesium
might also need to be supplemented, daily monitoring of
serum magnesium levels is also advisable.
Citrate clearance and metabolism
As depicted in Fig. 2, a large portion of CCC is removed
through the hemofilter [15]. CCC clearance is very high
(up to 60%) due to their low molecular weight (298
Daltons) associated with their high hydrosolubility con-
ferred by the negative charge of a free carboxylate rad-
ical. Their sieving coefficient is 1.0. The clearance must
be maintained as high as possible to minimize the
administration of citrate to the patient. This clearance
increases with the dialysate flow (the higher the dialysate
flow, the higher the clearance). In convective modes, cit-
rate’s clearance is dependent on filtration flow (the
higher the filtration flow, the higher the clearance). CCC
which are not removed through the hemofilter return to
the patient. They are metabolized in the liver, muscle,
and kidney fitting into the Krebs (citric acid) cycle.
Under normal conditions, citrate’s half-life is approxi-
mately 5 minutes. The process generates energy (2.48 KJ
or 593 calories per mmol of citrate), releases sodium as
well as calcium ions [16].
Citrate and acid-base balance
Acid-base consequences of RCA are often reduced to
bicarbonate generation by citrate metabolism. Unfortu-
nately, this simplification is inaccurate and correct un-
derstanding of citrate’s effect on acid-base balance
requires the use of Stewart’s global approach [17–19].
Briefly, according to this approach, blood pH is mainly
determined by three variables: PaCO2, strong ion differ-
ence (SID), and weak acids concentration. Citrate
belongs to the weak acid category and its effect should
be to markedly acidify a solution. Its three carboxylate
radicals have respective pKa values of 5.21, 4.28, and
2.92 at 25 °C) [20]. However, in plasma, unless the cal-
cium level is extremely low (to levels incompatible with
life), citrate is only present in the form of CCC. In that
form, its acidifying capacity is limited by the binding of
ionized calcium to two adjacent carboxylates, leaving
only one residual anionic charge (Fig. 3). Circulating
CCC therefore lead to mild plasma acidification. Under
normal conditions, this effect is negligible since CCC are
rapidly cleared from the blood.
However, the acid-base impact of RCA is not limited
to the effect of citrate itself. Indeed, the composition and
amount of dialysis/substitution fluid used are of major
importance. Many citrate solutions have a high sodium
content (three Na+ for one citrate molecule). This net
sodium administration tends to increase plasma SID
leading to plasma alkalinization.
Overall, when citrate catabolism is normal, RCA leads
to plasma alkalinization. This alkalinizing effect is max-
imal with trisodium citrate solutions and less marked with
ACD solutions (which have a low sodium content). To
some extent, this alkalinization is desirable as it buffers
acute kidney injury associated-acidosis and normalizes
pH. As discussed in further sections, in some clinical
Fig. 1 “ON-OFF” anticoagulation effect of ionized hypocalcemia. The
grey zone corresponds to the area of adequate anticoagulation.
Target values indicated are only indicative and depend on the
protocol used [12]
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situations where citrate catabolism is markedly impaired,
CCC tend to accumulate, generating a mild acidosis.
Citrate accumulation and alternative diagnoses
Citrate accumulation is a feared and potentially lethal
complication of RCA. Fortunately, when a strict protocol
is followed, it is rarely encountered [9]. In order to avoid
unnecessary therapy interruptions, it is essential for the
clinician to distinguish citrate accumulation from other
situations resulting in acid-base disturbance during
RCA: citrate net overload and insufficient trisodium-
citrate delivery. The main differences between these
entities are summarized in Table 1.
Citrate accumulation
The body’s capacity to metabolize citrate is saturable
(Fig. 4). If citrate administration exceeds this capacity,
residual citrate, in the form of CCC remain in blood. In
the absence of a routinely available assay for citrate
blood level, citrate accumulation can only be suspected
through indirect signs. The most reliable sign for citrate
accumulation is probably an increased total/ionized cal-
cium (Ca/Ca++) ratio. Indeed, an increase in this ratio
demonstrates an increase in the serum level of anion-
bound calcium, which in the context of RCA is almost
synonymous with circulating CCC. A cut-off value of 2.5
is usually recognized as indicative of significant accumu-
lation but a trend towards this value is highly indicative
of ongoing accumulation.
Other signs are commonly observed during citrate
accumulation. These signs should not be considered as
diagnostic criteria but represent warning signs of poten-
tial citrate accumulation. Of those, an increase in cal-
cium substitution needs might suggest the absence of
Fig. 2 Schematic view of a CRRT circuit with regional citrate administration in CVVHD mode. Alternative modes can be used (postdilution CVVH,
combined pre- and postdilution CVVH, CVVHDF, etc.) according to the protocol used. Citrate solution is administered at the beginning of the
CRRT circuit. It forms citrate–calcium complexes, which are largely removed from the blood at the level of the filter. Only complexes which are
not removed through the hemofilter return to the patient’s blood and need to be metabolized
Fig. 3 Citrate calcium complex. The distance between calcium’s two
positive charges corresponds to the distance between two citrate
carboxylate radicals. A carboxylate radical remains unbound,
providing residual anionic charge and a mild acidic effect. This
acidifying effect would be much stronger in vitro, in the absence of
ionized calcium
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CCC-bound calcium release and should prompt particu-
lar attention from clinicians. In overt citrate accumula-
tion, hypocalcemia is usually observed, potentially
leading to severe complications. Similarly, recurrence of
high anion gap metabolic acidosis and increased serum
lactate levels are also frequently observed concomitant
to citrate accumulation. These anomalies are not
thought to be secondary to citrate accumulation itself
but rather to a common primary process impairing the
tricarboxylic acid cycle, reducing citrate metabolism, and
limiting pyruvate metabolism leading to lactate gener-
ation. Accumulated CCC participate in the elevated anion
gap as well as to a strong ion gap. Pathophysiologic conse-
quences of CCC accumulation are presented in Fig. 5.
Net citrate overload
Net citrate overload is a common, benign, and easy to
manage complication of RCA. Citrate overload is a situ-
ation in which the organism’s capacity to metabolize cit-
rate is not reached and all citrate–calcium complexes
are metabolized (Fig. 4). The concomitant net load of
sodium ions leads to plasma alkalinization through an
increased SID. No increase in total/ionized calcium is ob-
served and ionized calcium levels remain normal. Net
Table 1 Citrate accumulation and alternative diagnoses: summary table
Citrate accumulation Citrate net overload Insufficient trisodium citrate delivery
Mechanism Incomplete citrate metabolism: persistence
of circulating citrate–calcium complexes in
the blood
Excess citrate administration
relative to buffer requirements
Insufficient alkalotic load administered to
the patient to adequately buffer acute
kidney injury-associated acidosis
Diagnosis
Acid-base Metabolic acidosis Metabolic alkalosis Metabolic acidosis
Catot/Cai ratio Increased (>2.5) Normal (< 2.5) Normal (< 2.5)
Other Increased need for calcium substitution
Trend for a decreased ionized calcium
level
None None
Appreciation Potentially lethal (via severe hypocalcemia) Benign and easy to fix Benign and easy to fix
Incidence Rare Common Rare
Management Decrease blood flow or increase dialysate
flow rate (if mild) Consider alternative
anticoagulation strategy
Decrease blood flow or increase
dialysate flow rate
Increase blood flow or decrease dialysate
flow rate
Fig. 4 Theoretical relationship between blood citrate level and citrate
load. a An increase in citrate load is not associated with an increase in
blood citrate level until a threshold is reached. This threshold corresponds
to the body’s capacity to metabolize citrate. b Certain circumstances, such
as severe liver failure or circulatory shock, might result in a lower threshold
corresponding to a decreased capacity to metabolize citrate (see text) Fig. 5 Consequences of citrate accumulation
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citrate overload is a sign of excessive citrate administra-
tion or, more frequently, of low clearance in the
hemofilter.
Insufficient trisodium-citrate delivery
Insufficient trisodium-citrate delivery is a situation where
the alkalotic load administered to the patient is insufficient
to adequately buffer acute kidney injury-associated acid-
osis, resulting in residual metabolic acidosis. This may
happen if blood flow is set too low proportional to dialys-
ate flow.
In this situation, the observed metabolic acidosis
should not be interpreted as resulting from citrate accu-
mulation. On the contrary, the adequate response should
be to increase the blood flow or to decrease the dialysate
flow. Key elements here are the normal total/ionized cal-
cium ratio and calcium substitution rate.
Situations at risk of citrate accumulation or net overload
Some situations lead to increased citrate delivery or de-
creased metabolizing capacity. According to the extent of
this process, and the patient’s ability to metabolize CCC, it
might lead to citrate accumulation or net overload (Fig. 4).
Excess citrate delivery to the patient
Accidental excess citrate infusion might occur in cases
of incorrect circuit setup (e.g.,post-filter citrate adminis-
tration) or administration of citrate when the blood
pump is stopped. These issues are now unlikely with
new generation CRRT devices with built-in citrate mod-
ules designed to prevent handling errors and increase
safety. In particular, citrate administration is coupled
with the blood pump. Such devices make use of specific
tubes and connections as well as color codes, minimiz-
ing the risk of errors during circuit setup and use.
Citrate removal at the hemofilter level can be impaired,
resulting in excess citrate delivery to the patient. Such an
issue might occur in CVVH mode when the ultrafiltration
rate is set too low or in CVVHD mode when an insuffi-
cient dialysate rate is set. These complications should be
prevented by adherence to a strict protocol. Rapid loss of
clearance at the filter level is occasionally observed in
some patients with early clogging of the membranes. In
such situations, the patient’s citrate delivery is higher than
expected by the mathematical model driving the pumps
and overload might occur. In this case, rapid replacement
of the circuit is necessary. Of note, such a situation is un-
likely to occur in CVVH mode, since early clogging would
be identified by an increased transmembrane pressure.
Most of these situations may be prevented by medical
and nursing education and their frequency should decrease
with increasing experience.
Decreased citrate metabolization
In some situations citrate metabolization is decreased
(Fig. 4b). A patient’s capacity to metabolize citrate is a
dynamic process depending on baseline characteristics
and hemodynamic status as well as mitochondrial func-
tion. Therefore, such situations are difficult to predict a
priori, but some groups of patients should be considered
at risk.
Patients with acute liver failure or acute-on-chronic
liver failure have classically been described as having
decreased citrate metabolizing capacity. However, recent
literature has suggested that most patients in these situa-
tions could process citrate anyway and that classic
markers of liver function were poor predictors of the
risk of citrate accumulation [21–23]. As depicted in
Fig. 4b, the ability of these patients to metabolize citrate
is not null but simply decreased. Therefore, a protocol
associated with low citrate delivery (normal or mildly
reduced doses associated to increased clearance) to the
patient is likely to be tolerated in most situations.
Patients with circulatory shock are likely to have a de-
creased oxygen delivery to the cells with decreased Krebs
cycle activity due to reduced activity of the mitochondrial
oxidation chain. Similarly, some commonly encountered
intoxications (biguanides (e.g., metformin), cyclosporine,
paracetamol, trichloroethylene, or propofol) can lead to
mitochondrial blockage and decrease citrate metaboliza-
tion capacity [24]. In these situations, a transient decrease
in citrate metabolizing capacity is likely.
Since all these situations are typically associated with
elevated serum lactate levels, such measurement is an
important indicator of the body’s capacity to metabolize
citrate. However, the lactate threshold above which RCA
should not be used remains to be determined.
Management
When either citrate accumulation or overload is sus-
pected, the net citrate load finally administered to the
patient must rapidly be decreased. According to the
protocol used, this can be obtained either by 1) decreas-
ing the blood flow rate (decreases intake through blood
flow–citrate coupling) or 2) increasing the dialysate rate
(CVVHD) or the filtration rate (CVVH) (increases
removal), or 3) decreasing the targeted citrate concen-
tration within the filter.
The two situations largely differ in potential severity
and consequences. Citrate accumulation usually occurs
in very severely ill patients. Unless rapid improvement
after citrate delivery decrease is observed, RCA should
be replaced by alternative circuit anticoagulation. Of
note, in this situation, CRRT should be continued to
enable CCC clearance. On the other hand, citrate over-
load is a benign process and should not prompt therapy
discontinuation. It is usually fixed with citrate delivery
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reduction. Normalization of the pH, however, is a slow
process and its correction requires time.
Minimizing the risk of citrate accumulation
A strict protocol for RCA should be applied in all cen-
ters for all patients. Particular care should be taken in
patients with suspected decreased citrate metabolization
capacity (acute liver failure, circulatory shock, and intox-
ications). In centers with limited experience with the
technique, RCA should probably be considered as con-
traindicated in such patients.
In addition to close monitoring of ionized calcium
(post-filter for efficacy and systemic for safety), regular
assessments of total/ionized Ca2+ and pH must be
performed.
In general, well-designed protocols should aim to
minimize citrate delivery to patients. This goal can be
achieved by combining several measures:
1. Limited blood flow should be used. Indeed, since
citrate administration is coupled to blood flow, lower
blood flow means less need for citrate. This can
easily be achieved in diffusion-based modes. Of note,
in diffusive modes, low blood flows do not translate
into low blood purification for two reasons: 1) di-
alysate rate remains the limiting factor and 2) high
flux membranes are preferred for RCA, allowing im-
portant clearance even with reduced blood flows.
Most protocols using diffusive modes would recom-
mend blood flow between 80 and 150 ml/min.
Purely convective techniques can be used but with a
higher risk of metabolic complications. Indeed, the
combination of low blood flows (to limit citrate ad-
ministration) and high filtration rates (to optimize
CCC clearance) would lead to high filtration frac-
tion, increasing the risk of membrane clogging and
decreased CCC clearance. This issue can be mini-
mized if diluted citrate solutions are used as
predilution.
2. High dialysate/filtration rates should be favored to
increase citrate removal.
Conclusions
Based on recent recommendations, the use of RCA is
likely to increase dramatically throughout the world.
RCA protocols should aim to minimize the amount of
net citrate load delivered to the patient. In case of acid-
base derangement during RCA, clinicians should be able
to differentiate a benign citrate net overload (alkalosis)
from a life-threatening accumulation (elevated Ca/Ca++,
increase need for calcium substitution, and trend toward
acidosis), which should prompt therapy tuning and early
termination. The distinction between these two entities
is crucial to enable adequate patient surveillance while
receiving RCA.
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